MiniMax上演逆袭。 作者 I 刘博 报道 I 投资界PEdaily 全球AI圈又沸腾起来了。 6月17号，Mi n iMa x "发布周"拉开序幕，又是开源又是发布新模型， 一系列动作令业内 惊呼。 新模型Mi niMa x-M1，是"世界上第一个开源的大规模混合架构的推理模型"，被 视为"性价比新王"。值得一提的是，这只是一道"开胃菜"。 Mi n iMa x，这个名字创投圈并不陌生。身后掌舵者是一位8 9年的博士——闫俊杰，他早 年任职于AI四小龙之一的商汤科技，后来在2 022年投身到AGI创业之中。早在Ch a tGPT 爆红前，Mi n iMa x就已经成为国产大模型的代表性企业。 1 9 8 9年，闫俊杰出生在河南的一座小县城。他从中国科学院自动化研究所博士毕业后， 继续在清华大学计算机系从事博士后研究。他的学术成就令人印象深刻——在深度学习和 计算机视觉领域，发表过顶级会议和期刊论文1 0 0余篇, Go ogl e Sc h o l a r引用超过10 0 0 0 次。 博士期间，闫俊杰加入商汤科技，从实习生一路做起，曾任商汤集团副总裁、研究院副院 长 和 智 慧 城 市 事 业 群 C ...

Core Viewpoint - Addex Therapeutics reported a strong start to 2025 with significant progress in product development and business milestones, particularly in their GABAB PAM drug candidate for chronic cough and regained rights to their Phase 2 mGlu2 PAM asset, ADX71149 [2][5]. Financial Summary - Income for Q1 2025 was CHF 71,000, a decrease of CHF 164,000 from CHF 235,000 in Q1 2024 [4]. - R&D expenses decreased to CHF 156,000 from CHF 245,000, a reduction of CHF 89,000 [4][8]. - G&A expenses decreased to CHF 521,000 from CHF 778,000, a reduction of CHF 257,000 [4][8]. - Total operating loss improved to CHF 606,000 from CHF 788,000, an improvement of CHF 182,000 [4]. - Net loss from continuing operations was CHF 1,473,000, compared to CHF 735,000 in Q1 2024, an increase of CHF 738,000 [4]. - Net loss for the period decreased to CHF 1,473,000 from CHF 3,087,000, a reduction of CHF 1,614,000 [4][9]. - Basic and diluted net loss per share was CHF 0.01, down from CHF 0.03 in the same period last year [4][10]. - Cash and cash equivalents increased to CHF 2.8 million from CHF 1.6 million, an increase of CHF 1.2 million [4][11]. - Shareholders' equity improved significantly to CHF 8.3 million from a negative CHF 1.4 million [4]. Operational Highlights - The GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple disease models [5][6]. - The company regained rights to its Phase 2 mGlu2 PAM asset, ADX71149 [5][6]. - Indivior successfully advanced their GABAB PAM program for substance use disorders through IND enabling studies [5][6]. - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6].

一位来自东莞工厂的负责人表示，现在整个市场缺货，只能每天寄出一定数量的现货，且价格比较高。 他建议采购者用下订单的形式采购，下订单之后15天左右陆续出货 。同时，该负责人还提到"现在外贸 下订单一堆，不用担心过气。" 近日，有媒体报道，随着LABUBU的持续火爆，一些仿冒工厂开始出现产能不足。 在批发平台上，有多个厂家正在生产、销售高仿版LABUBU。 有厂家告诉记者，目前货品供不应求， 如果订单需求量大，需要等两三天才能发出部分货品。也有厂家开始销售与原版差距较大 的"Lababa""Lagogo"，销量已达近万件 。 6月10日，记者以采购者的身份咨询了一家位于义乌的玩具公司，客服告诉记者，目前要货的人非常 多，要按顺序派单，如果需要1000个，可以安排明后两天陆续发出3件（720个）。客服还提到，有人一 口气订了5000个，大概到后天只能发出1200多个。一家位于安徽的工艺品公司表示，1000个LABUBU 需要三天时间发出。 截图自批发平台 生产和销售这种仿版LABUBU是否侵权？ 广东中安律师事务所合伙人、粤港澳大湾区国际仲裁中 心仲裁员潘翔表示，生产、销售LABUBU盗版产品存在如下法律风险：一是 ...

Core Viewpoint - Addex Therapeutics announced significant anti-tussive activity of its GABAB positive allosteric modulator (PAM) in preclinical models, indicating potential as a treatment for chronic cough [1][3][4] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [6] - The company’s lead drug candidate, dipraglurant, is being evaluated for brain injury recovery [6] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [6] Product Development - The GABAB PAM drug candidate demonstrated significant reductions in cough frequency and increased cough latency in preclinical models, outperforming reference drugs like nalbuphine, baclofen, and codeine [3][4] - The candidate showed better tolerability and a wider therapeutic margin compared to nalbuphine and baclofen, while being comparable to a P2X3 inhibitor [3] - The company is preparing to advance the GABAB PAM candidate into IND enabling studies following positive in vivo proof of concept [4] Scientific Background - GABAB receptors are crucial in the cough neural circuit, and activating these receptors has been clinically validated with baclofen, which has limitations due to side effects and loss of efficacy [5] - The allosteric modulation approach offers advantages such as higher selectivity and better tolerability compared to traditional orthosteric compounds [5]

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company announced the presentation of preclinical data for its GABAB positive allosteric modulator cough program at the 10th American Cough Conference [1][2] Company Overview - Addex's lead drug candidate is dipraglurant, a negative allosteric modulator targeting mGlu5, currently under evaluation for brain injury recovery [4] - The company is advancing an independent GABAB PAM program specifically for chronic cough, while also collaborating with Indivior on a GABAB PAM drug candidate for substance use disorders [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [4] Presentation Details - The presentation will be led by Mikhail Kalinichev, Head of Translational Science, discussing the antitussive efficacy of Compound A in guinea pig models [2][3] - The presentation is scheduled for June 7, 2025, at 11:20 am EST [7] Scientific Background - GABAB receptors are crucial in the cough neural circuit and are activated by the neurotransmitter GABA [3] - Current treatments like baclofen have limitations, and targeting allosteric sites may offer advantages such as higher selectivity and better tolerability [3]

作者 | 凌敏 没有什么比"群星闪耀"更适合形容近期的 TTS（Text-To-Speech，文本转语音）模型领域了。 开年以来，从科技巨头到创业公司再到研究机构，都在发力 TTS 模型。2 月，字节跳动海外实验 室推出一款轻量级 TTS 模型 MegaTTS3-Global；3 月，出门问问联合香港科技大学、上海交通 大学、南洋理工大学、西北工业大学等顶尖学术机构，共同开源新一代语音生成模型 Spark- TTS；同月，OpenAI 推出基于 GPT-4o-mini 架构的 TTS 模型。 与 AI 领域其他热门技术相比，TTS 似乎格外低调，但它却是智能硬件、数字人等场景的"隐形基 石"。凭借广泛的应用领域和开阔的商业前景，TTS 在最近一年取得了长足的进步，并悄然改变 着行业规则。 最近，TTS 模型又有重磅"上新"，Speech-02语音模型一出手，就将 OpenAI、ElevenLabs 甩在 了后面，登顶 Arena 榜单，成为全球第一。 | Creator | | Model | Arena ELO | 95% CI | # Appearances | | --- | --- | --- | - ...

Group 1 - The core viewpoint of the articles highlights a significant price increase across various consumer goods in the U.S. market due to the impact of tariffs imposed by the Trump administration, leading to concerns about inflation and reduced consumer demand [1][4]. - Amazon has seen an average price increase of 29% across nearly 1,000 products since April 9, affecting categories such as clothing, jewelry, home goods, electronics, and toys [2][4]. - Shein has raised prices significantly, with an average increase of 51% for its top 100 beauty and health products, and some kitchen items experiencing price hikes as high as 377% [3][4]. Group 2 - Major consumer goods companies like Procter & Gamble and Unilever have issued warnings about price increases, indicating potential inflationary pressures and a decline in consumer spending [4]. - Procter & Gamble has lowered its sales and profit forecasts, noting a decline in consumer spending in early 2023, and plans to raise prices further due to new tariffs [4]. - Unilever has increased prices by an average of 1.7% in the first quarter of 2025, citing rising costs for dairy, cocoa, and palm oil, exacerbated by new tariffs [4].

Core Viewpoint - Addex Therapeutics reported its full-year 2024 financial results, highlighting progress in clinical development and a significant net profit from discontinued operations, primarily due to the sale of part of its business to Neurosterix [1][4][8]. Financial Performance - Total income for 2024 was CHF 410,000, a decrease of CHF 1.2 million from CHF 1.6 million in 2023 [4][11]. - Research and Development (R&D) expenses decreased to CHF 854,000 from CHF 1.2 million, while General and Administrative (G&A) expenses also decreased to CHF 2.3 million from CHF 2.7 million [4][12]. - The total operating loss increased to CHF 2.8 million in 2024 from CHF 2.2 million in 2023 [4][13]. - Net loss from continuing operations was CHF 4.9 million, an increase of CHF 2.4 million compared to CHF 2.5 million in 2023 [4][13]. - The company reported a net profit of CHF 7.1 million for the period, primarily due to a net profit from discontinued operations of CHF 12.0 million [9]. Corporate Developments - The company launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A funding to advance its preclinical portfolio [6][7]. - Indivior selected a GABAB PAM drug candidate for development in substance use disorders, while Addex selected its own GABAB PAM for chronic cough [2][6]. - Addex regained full control of its mGlu2 PAM asset, ADX71149, and repositioned dipraglurant for brain injury recovery [2][6]. Cash Position - Cash and cash equivalents decreased to CHF 3.3 million at the end of 2024 from CHF 3.9 million at the end of 2023, primarily due to cash used in operating activities [10].

以下文章来源于解码LP ，作者岳笑笑 解码LP . 投资界（PEdaily.cn）旗下，专注募资动态 投向人工智能。 作者 I 岳笑笑 报道 I 投资界-解码LP 投资界-解码LP获悉，国家人工智能产业投资基金合伙企业（有限合伙）成立，出资额600.6亿元，落地上海市徐汇区。 这让人不禁想起，去年上海数支百亿规模人工智能产业基金先后建立、人工智能大会火爆等诸多难忘场景。如此一幕，也是全国各地 发力人工智能产业的一缕写照。 国家队出手 600亿AI大基金来了 | 序号 | 合伙人名称 | 出资比例 ÷ | 认缴出资额; | 认缴出资日期÷ 关联产品/机构 | | --- | --- | --- | --- | --- | | | 〗 ■▓ 国智投（上海）私募基金管理有限公司 孟 | | | 上海国盛投资 質闭 | | 2 | + 国家 国家集成电路产业投资基金三期股份有限公司 孟 | | | 国家集成电路 产业投资基金 | （图源天眼查） 先来看国家大基金三期——去年5月，注册资本高达3440亿人民币的国家大基金三期正式宣布成立，高于其一期9 87.2亿元和二期 2041. 5亿元规模的总和，成为国内史上规模最 ...

"如果我们在竞争中打不赢，就应该被淘汰，没有其他选择。 文丨程曼祺 由 MiniMax 视频生成大模型制作的短片《魔法硬币》，MiniMax 称其中每个场景都由大模型生成，未经任何修改。 发布会所在的 "西岸漩心" 被巨大的螺旋式阶梯环绕，游人可沿着步道一直走到顶层露台，眺望浦东风景。这 是一条上升、平缓，然后再上升、平缓，最终达到顶点的路。此时 AI 领域似乎也处在螺旋中的相对平缓期。 当 MiniMax 创始人闫俊杰放映完由视频生成模型制作的动画短片后，观众席传来数声尖叫。至少 3 位在场的 投资人说， 视频生成模型是他们当天最在意的成果 。 但视频生成模型本身不新鲜了，自 OpenAI 年初发布 Sora，数家中国公司跟进这一方向。 "期货" 也在成为行业关键词：GPT-5、GPT-4o 的语音视频功能、Sora……它们要么上线晚于预期，要么亮相多 时后仍未大规模公测。据我们了解，国内 "六小龙"（MiniMax、月之暗面、智谱 AI、百川智能、零一万物、 阶跃星辰 6 家大模型独角兽）今年的基础模型或多模态模型的更新时点也多晚于原计划。 发布结束后，闫俊杰被问起如何看待技术进展放缓。他说，一条上升、平 ...